HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Johan Bussink Selected Research

CCI 103F

2/2007Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers.
3/2006Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model.
7/2005Hypoxic cell turnover in different solid tumor lines.
9/2004Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Johan Bussink Research Topics

Disease

97Neoplasms (Cancer)
10/2022 - 09/2002
71Hypoxia (Hypoxemia)
10/2022 - 12/2002
37Squamous Cell Carcinoma of Head and Neck
01/2022 - 09/2002
22Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2020 - 07/2007
20Head and Neck Neoplasms (Head and Neck Cancer)
10/2022 - 12/2002
14Carcinoma (Carcinomatosis)
11/2017 - 12/2002
13Neoplasm Metastasis (Metastasis)
01/2022 - 02/2007
12Breast Neoplasms (Breast Cancer)
02/2020 - 08/2011
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2018 - 04/2003
7Lung Neoplasms (Lung Cancer)
01/2021 - 02/2006
5Necrosis
01/2022 - 07/2006
4Adenocarcinoma
12/2019 - 06/2012
4Glioblastoma (Glioblastoma Multiforme)
01/2018 - 02/2005
3Laryngeal Neoplasms (Laryngeal Cancer)
03/2014 - 10/2013
2Atherosclerosis
01/2020 - 01/2019
2Inflammation (Inflammations)
01/2020 - 01/2019
2Starvation
01/2018 - 08/2011
2Triple Negative Breast Neoplasms
01/2015 - 10/2011
2Colorectal Neoplasms (Colorectal Cancer)
03/2013 - 12/2012
2Sarcoma (Soft Tissue Sarcoma)
08/2012 - 06/2012
1Infections
01/2022
1Communicable Diseases (Infectious Diseases)
01/2022
1Bites and Stings (Sting)
01/2021

Drug/Important Bio-Agent (IBA)

28pimonidazoleIBA
01/2022 - 09/2002
24Proteins (Proteins, Gene)FDA Link
10/2022 - 03/2008
16Carbonic Anhydrase IXIBA
10/2022 - 12/2002
16ErbB Receptors (EGF Receptor)IBA
01/2016 - 06/2009
12Messenger RNA (mRNA)IBA
01/2022 - 08/2011
12Biomarkers (Surrogate Marker)IBA
10/2021 - 12/2008
11carbogenIBA
01/2022 - 12/2002
10Niacinamide (Nicotinamide)FDA LinkGeneric
01/2022 - 06/2002
10Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2017 - 06/2008
10Biological ProductsIBA
10/2014 - 05/2007
9Glucose (Dextrose)FDA LinkGeneric
12/2019 - 06/2007
9Cetuximab (Erbitux)FDA Link
01/2016 - 08/2011
9Phosphotransferases (Kinase)IBA
06/2015 - 06/2009
8Oxygen (Dioxygen)IBA
12/2021 - 09/2002
6Pentetic Acid (DTPA)FDA LinkGeneric
10/2022 - 08/2011
5bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
05/2012 - 09/2002
4Radioisotopes (Radionuclides)IBA
01/2022 - 07/2010
4RNA (Ribonucleic Acid)IBA
01/2022 - 01/2018
4TamoxifenFDA LinkGeneric
02/2020 - 02/2014
4MK 2206IBA
01/2020 - 10/2012
4alovudineIBA
04/2013 - 05/2007
4fluoroazomycin arabinosideIBA
09/2009 - 03/2008
4CCI 103FIBA
02/2007 - 09/2004
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 01/2007
3Glutamine (L-Glutamine)FDA Link
01/2022 - 12/2018
3Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
01/2022 - 01/2010
3Hypoxia-Inducible Factor 1IBA
01/2022 - 08/2011
3G250 monoclonal antibodyIBA
07/2021 - 01/2019
31,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
12/2019 - 02/2014
3Facilitative Glucose Transport Proteins (Glucose Transporter)IBA
12/2019 - 06/2012
3beta-Aminoethyl Isothiourea (AET)IBA
11/2018 - 10/2015
3Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
09/2014 - 03/2008
3Crystallins (Crystallin)IBA
04/2014 - 03/2013
3Small Interfering RNA (siRNA)IBA
09/2013 - 08/2011
3ParaffinIBA
09/2013 - 05/2010
2AntibodiesIBA
01/2022 - 01/2019
2RadiopharmaceuticalsIBA
01/2022 - 07/2010
2CytokinesIBA
01/2022 - 01/2020
2InterferonsIBA
01/2021 - 01/2018
2Estrogen ReceptorsIBA
02/2020 - 10/2011
2C-Type Lectins (C-Type Lectin)IBA
01/2020 - 01/2019
2mouse dectin-2IBA
01/2020 - 01/2019
2GlutaminaseIBA
12/2019 - 12/2018
2Contrast MediaIBA
01/2018 - 11/2017
2Chloroquine (Aralen)FDA LinkGeneric
01/2018 - 09/2013
2Monoclonal AntibodiesIBA
08/2015 - 07/2010
2Lysosomal Membrane ProteinsIBA
06/2015 - 09/2013
2MicroRNAs (MicroRNA)IBA
03/2015 - 01/2012
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
09/2014 - 11/2013
2Reactive Oxygen Species (Oxygen Radicals)IBA
04/2014 - 03/2013
2Growth Factor ReceptorsIBA
11/2013 - 03/2013
2Cadherins (E-Cadherin)IBA
10/2013 - 06/2011
2VimentinIBA
10/2013 - 06/2011
2Epidermal Growth Factor (EGF)IBA
09/2013 - 01/2007
2Activating Transcription Factor 4IBA
09/2013 - 01/2013
2Indicators and Reagents (Reagents)IBA
06/2013 - 04/2013
2Adenosine Triphosphate (ATP)IBA
06/2012 - 06/2008
2NitroimidazolesIBA
07/2010 - 12/2002
2Idoxuridine (Stoxil)FDA LinkGeneric
05/2010 - 05/2007
2fluoromisonidazoleIBA
10/2008 - 08/2006
1Bromodeoxyuridine (BrdU)IBA
01/2022
1Untranslated Regions (Untranslated Region)IBA
01/2022
1Immune Checkpoint InhibitorsIBA
01/2022
1LipopolysaccharidesIBA
01/2022
1Doxycycline (Periostat)FDA LinkGeneric
12/2021
1Autophagy-Related ProteinsIBA
12/2021
1Atovaquone (Mepron)FDA Link
07/2021
1cyclic guanosine monophosphate-adenosine monophosphateIBA
01/2021
1Interferon Type IIBA
01/2021
1DNA (Deoxyribonucleic Acid)IBA
01/2021

Therapy/Procedure

72Radiotherapy
01/2022 - 06/2002
45Therapeutics
10/2022 - 12/2002
11Drug Therapy (Chemotherapy)
01/2019 - 09/2004
10Aftercare (After-Treatment)
01/2018 - 09/2004
4Immunotherapy
01/2022 - 11/2019
4Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
01/2019 - 12/2016
4Chemoradiotherapy
11/2018 - 04/2013